A Systematic Review of Randomized Controlled Trials of Antibiotic Use in Diabetic Foot Ulcer Infections: Focus on Clinical Cure
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: The use of antibiotics in diabetic foot ulcer infections (DFUI) is essential in reducing morbidity. Optimal administration of antibiotics can improve clinical outcomes and reduce the risk of antibiotic resistance. This study aims to review the efficacy, in terms of clinical cure, of various regimens and the duration of antibiotic administration in DFUI patients, based on Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. The efficacy based on microbiological response is also reviewed as the secondary outcome. Materials and methods: We used three databases, namely PubMed, Scopus, and ScienceDirect, to search for randomized controlled trials (RCTs) in patients with DFUI who required antibiotics. Results: A total of 16 studies were included in the systematic review. The study locations and bacterial patterns varied, with the most common pathogen being Staphylococcus aureus. Most studies did not demonstrate a significant difference in clinical cure and pathogen eradication, either in the comparison between systemic and topical antibiotics or in the duration of administration. Some studies had similar characteristics and were analyzed to conclude. These studies showed that ertapenem had comparable efficacy to piperacillin/tazobactam. Similar results were also conducted from studies of piperacillin-tazobactam+amoxicillin-clavulanic acid vs. moxifloxacin. Conclusion: Most studies have heterogeneous characteristics, possibly due to differences in research location. Therefore, there is no strong evidence to recommend a specific antibiotic with the highest efficacy. However, since all included studies are RCTs, this review provides a good summary in considering antibiotic choices when treating DFUI patients.
Abstract
Background: The use of antibiotics in diabetic foot ulcer infections (DFUI) is essential in reducing morbidity. Optimal administration of antibiotics can improve clinical outcomes and reduce the risk of antibiotic resistance. This study aims to review the efficacy, in terms of clinical cure, of various regimens and the duration of antibiotic administration in DFUI patients, based on Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. The efficacy based on microbiological response is also reviewed as the secondary outcome. Materials and methods: We used three databases, namely PubMed, Scopus, and ScienceDirect, to search for randomized controlled trials (RCTs) in patients with DFUI who required antibiotics. Results: A total of 16 studies were included in the systematic review. The study locations and bacterial patterns varied, with the most common pathogen being Staphylococcus aureus. Most studies did not demonstrate a significant difference in clinical cure and pathogen eradication, either in the comparison between systemic and topical antibiotics or in the duration of administration. Some studies had similar characteristics and were analyzed to conclude. These studies showed that ertapenem had comparable efficacy to piperacillin/tazobactam. Similar results were also conducted from studies of piperacillin-tazobactam+amoxicillin-clavulanic acid vs. moxifloxacin. Conclusion: Most studies have heterogeneous characteristics, possibly due to differences in research location. Therefore, there is no strong evidence to recommend a specific antibiotic with the highest efficacy. However, since all included studies are RCTs, this review provides a good summary in considering antibiotic choices when treating DFUI patients.
참고문헌 (40)
- Saeedi P, "Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition", Diabetes Res Clin Pract, 157, pp.107843~ (2019)
- Lavery LA, "Risk factors for foot infections in individuals with diabetes", Diabetes Care, 29, pp.1288~1293 (2006)
- Ndosi M, "Prognosis of the infected diabetic foot ulcer : a 12-month prospective observational study", Diabet Med, 35, pp.78~88 (2018)
- Lipsky BA, "Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019update)", Diabetes Metab Res Rev, 36(Suppl 1), pp.e3280~ (2020)
- Wu WX, "Empirical antibiotic treatment in diabetic foot infection : A study focusing on the culture and antibiotic sensitivity in a population from Southern China", Int J Low Extrem Wounds, 16, pp.173~182 (2017)
- Uçkay I, "Principles and practice of antibiotic stewardship in the management of diabetic foot infections", Curr Opin Infect Dis, 32, pp.95~101 (2019)
- Barwell ND, "Diabetic foot infection : Antibiotic therapy and good practice recommendations", Int J Clin Pract, 71 (2017)
- MacGowan AP, "Antimicrobial therapy : principles of use", Medicine, 49, pp.635~641 (2021)
- Tamma PD, "Association of adverse events with antibiotic use in hospitalized patients", JAMA Intern Med, 177, pp.1308~1315 (2017)
- Dumville JC, "Topical antimicrobial agents for treating foot ulcers in people with diabetes", Cochrane Database Syst Rev, 6, pp.CD011038~ (2017)
- Tchero H, "Antibiotic therapy of diabetic foot infections : A systematic review of randomized controlled trials", Wound Repair Regen, 26, pp.381~391 (2018)
- Peters EJG, "Interventions in the management of infection in the foot in diabetes: a systematic review", Diabetes Metab Res Rev, 36(Suppl 1), pp.e3282~ (2020)
- Selva Olid A, "Systemic antibiotics for treating diabetic foot infections", Cochrane Database Syst Rev, 2015, pp.CD009061~ (2015)
- Jadad AR, "Assessing the quality of reports of randomized clinical trials : is blinding necessary?", Control Clin Trials, 17, pp.1~12 (1996)
- Manja V, "Epidemiology and clinical research design, part 1 : Study types", Neoreviews, 15, pp.e558~e569 (2014)
- Lauf L, "Phase 3 study comparing tigecycline and ertapenem in patients with diabetic foot infections with and without osteomyelitis", Diagn Microbiol Infect Dis, 78, pp.469~480 (2014)
- Lipsky BA, "Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers : a randomized, controlled, double-blinded, multicenter trial of pexiganan cream", Clin Infect Dis, 47, pp.1537~1545 (2008)
- Saltoglu N, "Piperacillin", tazobactam versus imipenem, Clin Microbiol Infect, pp.2010, 16[DOI]
- Vick-Fragoso R, "Efficacy and safety of sequential intravenous", oral moxifloxacin vs intravenous, clavulanate for complicated skin and skin structure infections, pp.Infection, 2009[DOI]
- Uçkay I, "A randomized controlled trial of the safety and efficacy of a topical gentamicin-collagen sponge in diabetic patients with a mild foot ulcer infection", SAGE Open Med, 6, pp.2050312118773950~ (2018)
- Uçkay I, "A randomized, controlled study to investigate the efficacy and safety of a topical gentamicin-collagen sponge in combination with systemic antibiotic therapy in diabetic patients with a moderate or severe foot ulcer infection", BMC Infect Dis, 18, pp.361~ (2018)
- Pham TT, "Moderate to severe soft tissue diabetic foot infections", Ann Surg (2021)
- Gariani K, "Three weeks versus six weeks of antibiotic therapy for diabetic foot osteomyelitis : A prospective, randomized, noninferiority Pilot Trial", Clin Infect Dis, 73, pp.e1539~45 (2021)
- Harkless L, "An open-label, randomized study comparing efficacy and safety of intravenous piperacillin", tazobactam and ampicillin, Surg Infect(Larchmt), pp.2005, 6[DOI]
- Lipsky BA, "Ertapenem versus piperacillin", tazobactam for diabetic foot infections(SIDESTEP) : prospective, randomised, controlled, double-blinded, multicentre trial, 2005, pp.366, 1695~1703
- Lipsky BA, "Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam", amoxicillin-clavulanate, 2007, pp.60, 370~376
- Schaper NC, "Efficacy and safety of IV", PO moxifloxacin and IV piperacillin, clavulanic acid in the treatment of diabetic foot infections : results of the RELIEF study, pp.Infection, 2013[DOI]
- Xu ZR, "Ertapenem versus piperacillin", tazobactam for diabetic foot infections in China : a Phase 3, multicentre, randomized, doubleblind, active-controlled, non-inferiority trial, 2016, pp.71, 1688~1696
- Patil SV, "Comparison of efficacy of levofloxacin-metronidazole combination versus ceftriaxone in cases of moderate diabetic foot infection", Int J Basic Clin Pharmacol, 5, pp.1775~1779 (2016)
- Tone A, "Six-week versus twelve-week antibiotic therapy for nonsurgically treated diabetic foot osteomyelitis : a multicenter open-label controlled randomized study", Diabetes Care, 38, pp.302~307 (2015)
- Lipsky BA, "Topical application of a gentamicin-collagen sponge combined with systemic antibiotic therapy for the treatment of diabetic foot infections of moderate severity : a randomized, controlled, multicenter clinical trial", J Am Podiatr Med Assoc, 102, pp.223~232 (2012)
- Macdonald KE, "The microbiology of diabetic foot infections : a metaanalysis", BMC Infect Dis, 21, pp.770~ (2021)
- Hawkins BK, "Diabetic foot infections : A microbiologic review", Foot, pp.101877~ (2021)
- Lipsky BA, "2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections", Clin Infect Dis, 54, pp.e132~e173 (2012)
- Hatipoglu M, "The microbiologic profile of diabetic foot infections in Turkey : a 20-year systematic review : diabetic foot infections in Turkey", Eur J Clin Microbiol Infect Dis, 33, pp.871~878 (2014)
- Rastogi A, "The microbiology of diabetic foot infections in patients recently treated with antibiotic therapy : A prospective study from India", J Diabetes Complications, 31, pp.407~412 (2017)
- Sekhar S, "Antimicrobial susceptibility pattern in diabetic foot ulcer : a pilot study", Ann Med Health Sci Res, 4, pp.742~745 (2014)
- Chow JW, "In vitro susceptibilities of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2002 Study for Monitoring Antimicrobial Resistance Trends (SMART)", Surg Infect(Larchmt), 6, pp.439~448 (2005)
- N Amirrah I, "Antibacterial-integrated collagen wound dressing for diabetes-related foot ulcers: An evidence-based review of clinical studies", Polymers(Basel), 12, pp.2168~ (2020)
- Khorramizadeh MR, "Aging differentially modulates the expression of collagen and collagenase in dermal fibroblasts", Mol Cell Biochem, 194, pp.99~108 (1999)